HIMS - Hims & Hers: The Undervalued Gem Poised For Growth

2024-06-18 03:05:48 ET

Summary

• As of this article being written, Hims & Hers Health is up around 33% since the announcement that they will offer GLP-1 Injections for as low as $199 a month.
• Reports that the company has already started shipping out injections to subscribers.
• HIMS stock is still undervalued despite the recent run-up in price, initiating a Buy rating based on subscriber growth, GLP-1 sales estimates, and increased revenues.
• Current revenue and EPS estimates don't factor in the addition of GLP-1 injections.
• Director at Hims, Christopher D. Payne, bought almost $2 million worth of stock, post GLP-1 announcement.

Editor's note: Seeking Alpha is proud to welcome Evan Urbanski as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » ...

For further details see: